Request under Freedom of Information Act 2000

Request Ref: NGFOI 19/20: 141

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 12/06/2019.

I am pleased to be able to provide you with the following information:

1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.
Yes

2. If yes, then how many MM patients, have been treated in the past 6 months with the following;

· Bortezomib [Velcade]	*
· Carfilzomib [Kyprolis]	*
· Ixazomib [Ninlaro]	**0**
· Lenalidomide [Revlimid]	**18**
· Daratumumab [Darzalex]	*
· Melphalan, prednisolone and thalidomide (known as MPT)	*
· Cyclophosphamide, thalidomide and dexamethasone (known as CTD)	**11**
· Pomalidomide [Imnovid]	**0**

*Due to the low numbers involved the exact figures have been withheld under the Freedom of Information Act, Exemption Section 40. This is to protect the identity of the individuals concerned and to preserve their rights under the Data Protection Act.

3. If you are able to split by therapy line for question 2, please indicate the number of patients above being treated, 1st line and 2nd line.
We are unable to split this information by 1ˢᵗ line and 2ⁿᵈ line

4. Does your trust treat adult/paediatric primary immune thrombocytopenia patients [ITP] ? - if you refer your adult/paediatric primary immune thrombocytopenia patients to another centre, please state which.
Yes, adult only

5. If yes, then of the treated adult/paediatric primary immune thrombocytopenia patients, how many are on the following;
- · *Eltrombopag [Revolade]* *
- · *Romiplostim [Nplate]* *

*Due to the low numbers involved the exact figures have been withheld under the Freedom of Information Act, Exemption Section 40. This is to protect the identity of the individuals concerned and to preserve their rights under the Data Protection Act.

6. At what line of treatment would you currently use a Thrombopoietin Receptor Agonist [TPO] (Eltrombopag [Revolade], Romiplostim [Nplate]) in an immune thrombocytopenia purpura [ITP] patient.
- · *1st*
- · *2nd*
- · *3rd*
- · *4th*

· *Unknown*
This would be patient dependant.

7. Do you treat patients with a Thrombopoietin Receptor Agonist TPO for the following diseases?

7a. Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy **No**
· *Eltrombopag [Revolade]*
· *Romiplostim [Nplate]*

7b.Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation **Not treated at NGH**
· *Eltrombopag [Revolade]*
· *Romiplostim [Nplate]*

7c. Chemotherapy induced thrombocytopenia (CIT) **None**
· *Eltrombopag [Revolade]*
· *Romiplostim [Nplate]*
· *7d myelodysplastic syndromes (MDS)*
· *Eltrombopag [Revolade]*
· *Romiplostim [Nplate]*

8. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?
12

9. If possible how many CLL patients treated were new to therapy in the past 3 months?
*Due to the low numbers involved the exact figures have been withheld under the Freedom of Information Act, Exemption Section 40. This is to protect the identity of the individuals concerned and to preserve their rights under the Data Protection Act.

10. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;
· *Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR)* **0**
· *Bendamustine and rituximab (known as BR)* *****
· *Ibrutinib [Imbruvica]* **9**
· *Chlorambucil* **0**
· *Venetoclax* **0**
· *Obinutuzumab* *****
· *Idelalisib* **0**
· *Fludarabine and rituximab (known as FR)* **0**
· *High-dose prednisone and rituximab* **0**
· *Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)* **0**
· *Alemtuzumab (Campath) with rituximab* **0**